Skip to content
DataLookout
Menu

NCT04598893

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

StatusCompleted
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 16 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 2 words Show 4 more changesShow less
    • Trial completed
    • Primary and study completion dates changed from estimate of Nov 2026 to Nov 12, 2026
    • Secondary endpoints: details revised at 1 of 3 entries
    • Site details revised at 19 of 47 sites
  2. Minor Site details revised at 3 of 47 sitesv17
  3. Notable Lead sponsor: Provention Bio, Inc. to Provention Bio, a Sanofi Companyv16
  4. Notable Primary endpoint revised
    • Secondary endpoints revised (3)
    v15
  5. Notable Eligibility criteria revisedv14 Show 5 more changesShow less
    • Primary endpoint revised
    • Enrollment target: estimated 200 to confirmed 188
    • Secondary endpoints expanded, about 18 words
    • Study description expanded, about 2 words
    • Study title expanded, about 2 words
Show 10 earlier versionsHide 10 earlier versions
  1. Minor Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Primary and study completion dates: Jun 2026 to Nov 2026
    v13
  2. Minor Study sites: 42 to 47v11
  3. Minor Study sites revised (42)v9
  4. Minor Study sites: 34 to 42v8
  5. Minor Study sites: 31 to 34v7
  6. Minor Study sites: 25 to 31v6
  7. Minor Study sites: 18 to 25v5
  8. Minor Study sites: 1 to 18v4
  9. Minor Start date changed from estimate of Nov 2020 to Oct 26, 2020v3
  10. Minor Start date: Oct 2020 to Nov 2020v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs), including infections and malignancies
Timeframe: During 42 months of follow-up

Secondary (3)

Area under the time-versus concentration curve (AUC) of C-peptide after a 4-hour (4h) mixed-meal tolerance test (MMTT)
Insulin use (daily average insulin dose in U/kg/day)
HbA1c

Arms and interventions

Teplizumab

Participants who received teplizumab in the PROTECT study

Placebo

Participants who received placebo in the PROTECT study

Biologicals: Teplizumab

Other: Placebo

Sites

47 sites in 8 countries

United States 25, France 7, Germany 5, Poland 4, Belgium 2, Canada 2, Czechia 1, United Kingdom 1